OCTUSDT
OracleChain / Tether USD
crypto

the great choppening of OCT 1st

Everyone remember WATM Puts? I have an OCT 30 $765P position on SPY and I am selling $763-765 Puts against it 2 to 4 days out. Been very productive the last week.

01 OCT 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?

BTC +2 BNO 100 (Weeklys) 30 OCT 26 (29) 55/50 P @.69, +45%,

I agree, as far as biotech stocks go, OMER is fairly safe. Very low debt now, since they used the upfront payment from NOVO to pay off a majority of their debt. They have an upcoming $100 million milestone payment from Novo that mgmt has said is “in the near term”, which I would think it means before the end of the year (speculation on my part).
EMA will most likely be reevaluating Yartemlea in their October meetings for possible EU approval. Yartemlea sales in 2q blew away everyone’s expectations. I was hoping for $15 million revenue, which I thought would be great progress for a drug in its first full quarter of commercial sales, but OMER made $32.2 million in gross revenue
For 3q, with j-code starting in July, I think Yartemlea could generate $50+ million in gross revenue for the quarter. NTAP status for Yartemlea starts today (OCT 1st). Cantor recently estimated max annual sales of Yartemlea reaching $400 million. I think that is conservative imo.
I think it is still undervalued at $1.4 billion. Based on my DD, I think this company is worth at least $2.5 billion right now.

the great choppening of OCT 1st

Everyone remember WATM Puts? I have an OCT 30 $765P position on SPY and I am selling $763-765 Puts against it 2 to 4 days out. Been very productive the last week.

01 OCT 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?

BTC +2 BNO 100 (Weeklys) 30 OCT 26 (29) 55/50 P @.69, +45%,

I agree, as far as biotech stocks go, OMER is fairly safe. Very low debt now, since they used the upfront payment from NOVO to pay off a majority of their debt. They have an upcoming $100 million milestone payment from Novo that mgmt has said is “in the near term”, which I would think it means before the end of the year (speculation on my part).
EMA will most likely be reevaluating Yartemlea in their October meetings for possible EU approval. Yartemlea sales in 2q blew away everyone’s expectations. I was hoping for $15 million revenue, which I thought would be great progress for a drug in its first full quarter of commercial sales, but OMER made $32.2 million in gross revenue
For 3q, with j-code starting in July, I think Yartemlea could generate $50+ million in gross revenue for the quarter. NTAP status for Yartemlea starts today (OCT 1st). Cantor recently estimated max annual sales of Yartemlea reaching $400 million. I think that is conservative imo.
I think it is still undervalued at $1.4 billion. Based on my DD, I think this company is worth at least $2.5 billion right now.

In the Accumulation phase, there is a secondary push towards the bear market bottom, which is determined in the Consolidation phase. This is necessary for two reasons. To appease doubts that the bottom isn't truly in yet, and to shakeout the majority of bagholders. Keep in mind that people with a high average cost, especially those being dragged across the floor for two years at bear market lows, are looking for an exit opportunity. The first attempt to exit consolidation, although it can appear as a major bullish divergence, always has been shot down by eager sellers. Now in 2024/2025, there was a LOT of buyers as well, which is why that large crawl upwards did take place. But in the end, sellers won the fight and buying pressure was exhausted before selling pressure. The flash crash of OCT 10th was the final nail in the coffin, which broke through major support levels in a matter of hours, forcing leveraged long traders to sell at very undesirable prices, reintroducing sharp fear into the market, and ultimately killed that rally. That is why the Accumulation phase is so important.

OCT 7th we will soon find out

couple large buys
12:51 PM BUY +549 GME 100 (Weeklys) 2 OCT 26 23.5 CALL @1.35 LMT
12:51 PM BUY +741 GME 100 (Weeklys) 2 OCT 26 25 CALL @.41 LMT
1:14 PM BUY +741 GME 100 (Weeklys) 2 OCT 26 25 CALL @.38 LMT
1:17 PM BUY +721 GME 100 16 OCT 26 24 CALL @1.56 LMT
1:17 PM BUY +828 GME 100 16 OCT 26 24 CALL @1.55 LMT
1:19 PM BUY +827 GME 100 16 OCT 26 24 CALL @1.49 LMT

Anyone waiting for $TSM earnings on OCT 15th ?

If the FED raises again in OCT. the beating will be severe